Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The new challenges for chemotherapy research.

J Grosset1

  • 1Faculté de Médecine Pitié-Salpêtrière, Paris, France.

Leprosy Review
|February 24, 2001
PubMed
Summary

Multidrug therapy (MDT) is crucial for leprosy control. Research aims to improve MDT accessibility and develop shorter, supervised treatment regimens for all leprosy patients, addressing current therapy limitations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Antimicrobial agents and chemotherapy·2010
Same author

Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease.

The European respiratory journal·2005
Same author

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Antimicrobial agents and chemotherapy·2005
Same author

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Antimicrobial agents and chemotherapy·2005
Same author

A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries.

Microbial drug resistance (Larchmont, N.Y.)·2005
Same author

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2004

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Leprosy control relies solely on multidrug therapy (MDT) due to the absence of an effective vaccine.
  • Current MDT regimens face challenges including long duration, complex patient classification, and reliance on daily self-administration.
  • Ensuring equitable access to MDT for all leprosy patients, especially in remote areas, remains a priority.

Purpose of the Study:

  • To highlight the need for adapting leprosy treatment strategies to evolving scientific knowledge and patient needs.
  • To identify key areas for improvement in leprosy case-finding and multidrug therapy (MDT) quality.
  • To advocate for research into new drug regimens that overcome the limitations of current WHO-recommended treatments.

Main Methods:

  • Review of current leprosy control strategies and challenges.
  • Analysis of the shortcomings of existing multidrug therapy (MDT) regimens.
  • Identification of research priorities for developing improved leprosy chemotherapy.

Main Results:

  • Multidrug therapy (MDT) is the sole available tool for leprosy control.
  • Existing MDT regimens are lengthy, require precise patient classification (PB/MB), and depend on daily self-administration.
  • Gaps exist in case-finding, MDT quality, and delivery to underserved populations.

Conclusions:

  • There is an urgent need to improve the accessibility and quality of multidrug therapy (MDT) for leprosy.
  • Research should focus on developing shorter, fully supervised MDT regimens effective for both paucibacillary (PB) and multibacillary (MB) leprosy.
  • Existing drugs may allow for the development of improved regimens, necessitating clinical trials for validation.

Related Experiment Videos